Logo Boehringer Ingelheim

Advisory Board

Expand all CVs×Hide all CVs

Philipp von Lattdorf

Chairman Advisory Board

More about:
Philipp von Lattdorf

CV

Philipp von Lattorff (Chairman Advisory Board ViraTherapeutics) started his career at IBM Austria in 1991. Two years later, he joined Boehringer Ingelheim, Vienna, in the area management for Eastern Europe. Other significant stages along his way were management functions in the Baltic region, in Hungary and Italy as well as Regional Business Management Positions for Europe and as CEO for the Central and Eastern European region for CSC pharmaceuticals. In 2011, he joined Boehringer Ingelheim as Head of Emerging Markets before taking over his current role as Country Managing Director of the Boehringer Ingelheim Regional Center Vienna in 2013 where he is responsible for the company’s pharmaceutical business in more than 30 countries in Central and Eastern Europe, Central Asia and Israel.

×Show less
 

Dr. Jonathon Sedgwick

More about:
Dr. Jonathon Sedgwick

CV

Jonathon Sedgwick, B.Sc. (Hons) Ph.D. born Perth Australia, is an Immunologist, educated at the University of Western Australia with post-doctoral education at the University of Oxford. His subsequent career included positions in academic research in Germany and Australia, Group Director Immunology at the biotech Company DNAX, in Palo Alto, California and 11 years with Eli Lilly and Company where he held a number of roles including Chief Scientific Officer, Cancer Inflammation Research; Managing Director and Chief Scientific Officer of Lilly’s Singapore Research Center, and Chief Scientific Officer, Autoimmunity Discovery. In November 2015, Dr. Sedgwick joined Boehringer Ingelheim, based at the Ridgefield CT USA research site. He holds the position of Vice President and Global Head Cancer Immunology and Immune Modulation Research. He has responsibility across four global sites for the development of the Immuno-oncology discovery and early clinical portfolio, and for immune-modulation research. Amongst his key contributions to the immunology field was the discovery with colleagues at DNAX of the dominant biological role of the interleukin-23 cytokine in autoimmune inflammation, and through this identifying the IL-17-producing T cell subset, Th17. These discoveries have underpinned a number of breakthrough medicines in the autoimmunity field. Dr. Sedgwick has authored or co-authored 120 peer-reviewed, review articles and book chapters.

×Show less

Dr. Ralf Schumacher

More about:
Dr. Ralf Schumacher

CV

Besides serving as a member of the Supervisory Board of ViraTherapeutics, Dr. Ralf Schumacher is currently the Head of Development Biologicals in the Development Unit within Boehringer Ingelheim. In this capacity, he is accountable for all non-clinical development activities which are required to bring a biological clinical candidates into clinics and subsequently through clinical development up to launch. Corresponding disciplines comprise all CMC functions (from cell line development, USP, DSP, Analytics, Formulation, Primary Packaging up to Combination Product development), DMPK (bioanalytical method development, PK & ADA studies in animals and humans), and non-clinical drug safety. Soon, a unit for clinical trial supplies will be added. The units are located in Germany and the US. Boehringer Ingelheim is committed to innovation and strives for development of first-in-class Biologicals with breakthrough potential. The Biologicals' portfolio includes monoclonal antibodies, engineered multi-functional NBEs, and new (ATMP) modalities.

×Show less